AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company based in Switzerland that develops medicines and diagnostics for neurodegenerative diseases driven by misfolded proteins. Its work centers on two proprietary platforms, SupraAntigen® and Morphomer®, which it uses to build therapeutic and diagnostic programs for Alzheimer’s disease, Parkinson’s disease, ALS and related indications.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueConformation-specific biologics designed to prevent or treat neurodegenerative disease biology.
Morphomer-based small-molecule candidates aimed at misfolded protein targets.
PET and related diagnostic programs intended to detect neurodegenerative pathology.
Upfronts, milestones and royalties from partnered development programs.
Customers
AC Immune’s direct customers are primarily large pharmaceutical partners that license programs, fund development, and may commercialize approved assets. Its end users are patients, clinicians and healthcare systems in neurology and neurodegeneration, where diagnostic clarity and disease-modifying therapies are needed. The company also serves research-oriented collaborators that support platform validation and pipeline advancement.
Buy access to discovery programs, development rights and potential commercial rights for lead assets.
Use eventual approved therapies and diagnostics in Alzheimer’s, Parkinson’s and related diseases.
Use PET tracers and diagnostic tools to identify pathology and support precision medicine.
Support preclinical validation, translational work and biomarker development.
Strategy
The company’s strategy is built around a three-pillar model: Alzheimer’s disease, other neurodegenerative diseases such as Parkinson’s and ALS, and diagnostics. It seeks to turn proprietary platform science into partnered and proprietary programs that can attract non-dilutive funding, milestones and royalties while preserving optionality across multiple disease targets.
Clinical validation is the main path to value creation for a platform biopharma company.
Upfronts, milestones and royalties reduce funding needs and diversify risk.
Multiple indications increase the usable addressable market and platform relevance.
Diagnostics can improve patient selection and support commercialization of therapies.
Geography
AC Immune is headquartered in Lausanne, Switzerland and operates through a Swiss parent company with a U.S. subsidiary in Delaware. Its business is global in nature because partnerships, clinical development and intellectual property exploitation span North America, Europe and other major pharmaceutical markets.
Risks
AC Immune depends on successful clinical development, regulatory clearance and partner execution, all of which are uncertain in neurodegenerative disease. Its revenue model is exposed to collaboration timing and milestone concentration, while its R&D-heavy structure makes capital allocation, trial outcomes and impairment judgments especially important.
- Clinical development failureImpact: CriticalLikelihood: High
Pipeline value depends on proof of mechanism and clinical efficacy in difficult neurodegenerative diseases.
Exposure: Phase 2 and Phase 3 assets
- Partner concentration and milestone dependenceImpact: HighLikelihood: Medium
A meaningful part of value creation comes from collaboration agreements and milestone payments.
Exposure: Licensing and partnership agreements
- Regulatory and trial timeline delaysImpact: HighLikelihood: Medium
Drug and diagnostic approvals require multi-stage testing and agency review.
Exposure: Therapeutics and diagnostics
- Funding and dilution riskImpact: HighLikelihood: Medium
A clinical-stage biotech typically relies on external capital before product sales emerge.
Exposure: Cash burn and financing needs
- Impairment of IPR&D assetsImpact: MediumLikelihood: Medium
Capitalized intangibles and development assets can be written down if programs underperform.
Exposure: Intangible assets
Accounting
Judgemental itemsUpfront payments, milestones and licensing deliverables may be recognized over time or at points in time.
Impact: Can cause uneven reported revenue
Trial costs are estimated based on work performed by CROs and investigators.
Impact: Can shift expense recognition across periods
Development assets depend on scientific and regulatory progress.
Impact: Can create large non-cash charges if programs weaken
Equity awards are a meaningful non-cash employee cost for biotech companies.
Impact: Affects operating expenses and equity
Office and laboratory leases create right-of-use assets and lease liabilities.
Impact: Impacts balance sheet leverage and expense profile
Similar listed companies
Publicly listed companies with a comparable business focus.
Voyager Therapeutics, Inc.
VYGR · Biological Products, (No Diagnostic Substances)
ProMIS Neurosciences Inc.
PMN · Pharmaceutical Preparations
Prothena Corporation plc
PRTA · Pharmaceutical Preparations
Prothena Corp.
Immunome Inc.
IMNM · Pharmaceutical Preparations
Cognition Therapeutics, Inc
CGTX · Biological Products, (No Diagnostic Substances)
Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on small-molecule therapies for age-related degenerative diseases of the central nervous system and retina.
Immuneering Corp
IMRX · Pharmaceutical Preparations
Immuneering Corp is a clinical-stage biotechnology company focused on developing oncology therapies, with an emphasis on MAPK pathway cancers and biomarker-driven patient selection.
Last updated: 28/09/2026